NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C

Journal of Hepatology

Volumn 54, Issue 5, 2011, Pages 1069-1072

  Asselah, Tarik ^a,b  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Boceprevir; IL28B; Interferon lambda; Pegylated interferon; Polymerase inhibitors; Protease inhibitors; Ribavirin; Telaprevir

Indexed keywords

ABT 072; ABT 450; AMINO ACID; ANTIVIRUS AGENT; BI 201335; BI 297127; BMS 650032; BMS 790052; BOCEPREVIR; DANOPREVIR; DIRECT ACTING ANTIVIRAL; GS 9190; GS 9256; IDX 184; IDX 320; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON; PLACEBO; PROTEIN INHIBITOR; PROTEINASE; RG 7128; RIBAVIRIN; SERINE PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; VX 222;

DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; GENOTYPE; HEPATITIS C; HUMAN; IN VITRO STUDY; INFECTION RATE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPLICON; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRION; VIRUS CULTURE; VIRUS GENOME; VIRUS LOAD;

EID: 79954831999     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.033     Document Type: Note

References (22)

1. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
2. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362 (Pubitemid 19117877)
3. T. Asselah, I. Biche, A. Sabbagh, P. Bedossa, R. Moreau, and D. Valla Gene expression and hepatitis C virus infection Gut 58 2009 846 858
4. S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, and D. Cazals-Hatem Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
5. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
6. T. Asselah, I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, and M.P. Ripault Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut 57 2008 516 524
7. T. Asselah, Y. Benhamou, and P. Marcellin Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int 29 2009 57 67
8. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Telaprevir in combination with peginterferon Alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study. Hepatology 52, AASLD 2010; Abstract LB-2.
9. Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy R, Bzowej NH, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of Phase 3 ADVANCE study. Hepatology 52, AASLD 2010; Abstract 211.
10. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, and N.H. Afdhal Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
11. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
12. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir combined with peginterferon alfa-2b/ribavirin for treatment-naive patients with hepatitis C virus genotype 1: SPRINT-2 final results. Hepatology 52, AASLD 2010; Abstract LB-4.
13. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. HCV RESPOND-2 final results: high sustained virological response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin. Hepatology 52, AASLD 2010; Abstract 216.
14. E. Gane, S. Roberts, C. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
15. T.P. Holler, T. Parkinson, and D.C. Pryde Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase Expert Opin Drug Discov 4 2009 3
16. R.A. Love, O. Brodsky, M.J. Hickey, P.A. Wells, and C.N. Cronin Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus J Virol 83 2009 4395 4403
17. B.R. Stockwell Exploring biology with small organic molecules Nature 432 2004 846 854 (Pubitemid 40037140)
18. J.A. Lemm, D. O'Boyle 2nd, M. Liu, P.T. Nower, R. Colonno, and M.S. Deshpande Identification of hepatitis C virus NS5A inhibitors J Virol 84 2010 482 491
19. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
20. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib RH, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology 52, AASLD 2010; Abstract LB-8.
21. Zeuzem S, Buggisch P, Agarwal K, Manns MP, Marcellin P, Foster G, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects. Hepatology 52, AASLD 2010; Abstract LB-1.
22. Zeuzem S, Asselah T, Angus PW, Zarski JP, Larrey D, Mullhaupt B, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Hepatology 52, AASLD 2010; Abstract LB-7.